Barrera J M, Bruguera M, Ercilla M G, Sánchez-Tapias J M, Gil M P, Costa J, Gelabert A, Rodés J, Castillo R
Hospital Clinic i Provincial, University of Barcelona, Spain.
Ann Intern Med. 1991 Oct 15;115(8):596-600. doi: 10.7326/0003-4819-115-8-596.
To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels.
Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis.
The blood-transmitted viruses unit and the liver unit of a university teaching hospital.
A total of 250 patients who had open heart surgery and their 3142 blood donors.
Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up.
Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33 mukat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis.
Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.
比较筛查献血者丙型肝炎病毒抗体(抗-HCV)对受血者非甲非乙型肝炎发病率的影响,与筛查献血者乙肝核心抗原抗体(抗-HBc)及丙氨酸转氨酶水平升高的影响。
对献血者和受血者血清样本进行队列分析。对受血者随访12个月以确定非甲非乙型肝炎的发生情况。
一所大学教学医院的血液传播病毒科和肝病科。
250例接受心脏直视手术的患者及其3142名献血者。
采用酶联免疫吸附测定(ELISA)检测献血者血清中的抗-HCV,若结果为阳性,则采用重组免疫印迹法(RIBA)检测。同时检测抗-HBc抗体和血清丙氨酸转氨酶(ALT)水平。在输血前及随访期间定期检测受血者的抗-HCV和ALT活性。
250名输血受血者中,40例发生了非甲非乙型肝炎。3142名献血者中,70例ELISA检测抗-HCV阳性,440例抗-HBc阳性,177例丙氨酸转氨酶水平在0.67至1.33 mukat/L之间。献血者筛查中,抗-HCV的敏感性(87%)、特异性(89%)、阳性预测值(59%)和阴性预测值(97%)高于抗-HBc(分别为82%、36%、21%和91%)以及丙氨酸转氨酶(分别为70%、29%和91%)。因抗-HCV阳性而被排除的献血者预期数量远少于因肝炎替代标志物检测结果阳性的献血者。
筛查献血者是否存在抗-HCV比筛查替代标志物(抗-HBc和ALT)更准确,能更有效地预防输血后非甲非乙型肝炎。